BM SLPC versus LLPC had 140 DEG for SLE and 28 DEG for HD. For both SLE versus HD, there were 52 DEG for LLPC, 22 DEG for SLPC, 180 DEG for PBL PB and 35 DEG for BM transitional B cells. Thus, ...

16, 2025 /PRNewswire/ -- After increases over the past three years, the five-year relative survival rate for pancreatic cancer remains flat at 13%, and just 8% for people diagnosed with the most ...

1Masonic Cancer Center, Minneapolis, Minnesota. 6Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota. 7Department of ...

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and New Treatments for Patients LOS ANGELES, Jan. 16, 2025 /PRNewswire/ -- After ...

and analyzed the interactions of the different subtypes with other cell populations in the TME by cellular communication. We also analyzed a protective pericyte subpopulation and a cancer-promoting ...

Autologous SUPLEXA is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According to GlobalData, Phase I drugs for ...

Nammi Therapeutics (Nammi) is a immuno-oncology company developing products for the treatment of cancer. The company product portfolio includes QLX138AM, SLNP-IC1 and NTI-121. Nammi’s lead product ...